Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2020-02-10 Director's Dealing
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice MC 2 pages 138.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held and interests in contracts. There is no financial performance data, earnings information, or report content. Instead, it is a notification of a director's personal shareholdings and interests, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, confirming it is not a full report or announcement of a report. Therefore, the correct classification is Director's Dealing (DIRS).
2020-02-10 English
Final Director's Interest Notice RT 2 pages 207.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and cessation of directorship. The content is focused on reporting personal share transactions and holdings of a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, not a broader financial or management report.
2020-02-10 English
Appendix 4C - Quarterly 9 pages 368.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report' and is dated 31 January 2020. It contains detailed descriptions of clinical development progress, corporate updates, and a consolidated statement of cash flows for the quarter ended 31 December 2019. The presence of the Appendix 4C Quarterly Cash Flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly report with substantive financial data and operational updates. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes financial figures, clinical study progress, and cash flow statements, which are typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-01-30 English
Botanix receives A$7.6m R&D Tax Incentive refund 2 pages 161.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 29 January 2020 announcing that Botanix Pharmaceuticals has received an R&D Tax Incentive refund of A$7.6 million for the 2018/2019 financial year. It discusses the financial impact of the refund and updates on clinical study progress. There are no detailed financial statements, comprehensive financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a financing-related event (receipt of a government tax refund) that strengthens the company's financial position. This fits best under Capital/Financing Update (CAP) as it relates to company financing activities and cash inflows. The document length is about 4705 characters, which is consistent with a press release rather than a full report. Therefore, the classification is CAP with high confidence.
2020-01-28 English
Botanix Attends USA Healthcare Conferences 32 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated January 13, 2020, announcing Botanix Pharmaceuticals' attendance at healthcare conferences and providing updates on clinical studies and company programs. It includes a presentation used at the conferences, detailed company and product information, pipeline status, and team bios. The content is promotional and informational about company strategy, clinical progress, and near-term milestones, typical of an investor presentation. There are no financial statements, regulatory filings, or voting results. The document is lengthy (15,000 characters) and contains detailed presentation slides and company overview, consistent with an Investor Presentation (IP).
2020-01-12 English
Change of Director's Interest Notice RT 4 pages 402.0KB
Director's Dealing Classification · 100% confidence The document is an ASX/Media Release dated 23 December 2019 regarding a Change of Directors Interest Notice for Robert Towner. It includes detailed information about the director's securities transactions, including the number of shares disposed and held before and after the change, the nature of the transaction (off-market transfer), and compliance with ASX Listing Rule 3.19A. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings. There is no indication that this is a full financial report, earnings release, or other types of filings. The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive disclosure of insider trading activity by a director.
2019-12-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.